Black women are disproportionately diagnosed with advanced-stage ovarian and breast cancers compared with White women, according to a report from COTA, a real-world data company focused on cancer care. These inequities in detection are compounded by …
The prototype of a new machine that can detect tumors in women with dense breast tissue has been developed by researchers from UCL, Newcastle Hospitals and Newcastle University, in partnership with international technology group Kromek. All breasts are …
Have you ever thought about what’s really inside your shampoo, moisturizer, or makeup? It turns out, many everyday beauty products might be carrying hidden risks, especially for women’s health. Breast Cancer UK is raising the alarm about chemicals called …
A brave single Colorado mother who was battling breast cancer for a fourth time tragically died after a stray bullet flew through her window. Jennifer James, 49, was undergoing chemotherapy when she was struck by a bullet while sitting inside her Berthoud …
COLUMBUS, Ohio (WCMH) — The annual Susan G. Komen Columbus Race for the Cure is this Saturday, and every year, thousands participate with the goal of raising money for breast cancer research and treatment. NBC4 is a proud sponsor for the race that brings …
A groundbreaking genetic study conducted in South Africa has unveiled two novel genetic variants that are implicated in breast cancer among black South African women. This discovery marks the first genome-wide association study (GWAS) of breast cancer …
Elizabeth Hurley and her son, Damian Hurley, stepped out together for the 2025 Breast Cancer Research Foundation Hot Pink Party held at Glasshouse on Tuesday in New York City. The actress was on theme for the event, wearing a bright pink sheer floral gown …
The addition of adjuvant pertuzumab (Perjeta) to trastuzumab (Herceptin) and chemotherapy led to a significant improvement in overall survival (OS) vs placebo plus trastuzumab and chemotherapy in patients with early-stage, HER2-positive operable breast …
Ribociclib (Kisqali) plus endocrine therapy generated low pathologic complete response (pCR) rates that were similar to those seen with standard-of-care (SOC) chemotherapy in patients with intermediate-risk hormone receptor (HR)–positive, HER2-negative …
&
